52
Participants
Start Date
June 3, 2024
Primary Completion Date
April 1, 2025
Study Completion Date
June 1, 2025
Diponecaftor
"Diponecaftor is a triple combination of DIR/POS/NES. The combination therapy will be administered orally during 8 weeks. The daily dose contains:~* DIR 300 mg/day~* POS 600 mg/day~* NES 10 mg/day"
Placebo
Placebo once daily for 8 weeks. Oral administration.
NOT_YET_RECRUITING
UZ Leuven, Leuven
NOT_YET_RECRUITING
CHU de Nice, Nice
NOT_YET_RECRUITING
Hôpital Larrey CHU Toulouse, Toulouse
NOT_YET_RECRUITING
Charité Universitätsmedizin Berlin, Berlin
NOT_YET_RECRUITING
Medizinische Hochschule Hannover, Hanover
NOT_YET_RECRUITING
Instituto Giannina Gaslini, Genova
NOT_YET_RECRUITING
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan
NOT_YET_RECRUITING
Ospedale Pediatrico Bambino Gesù, Rome
NOT_YET_RECRUITING
Azienda Ospedaliera Universitaria Integrata, Verona
NOT_YET_RECRUITING
Hospital de Santa Maria, Lisbon
NOT_YET_RECRUITING
Hospital Vall d'Hebron, Barcelona
RECRUITING
Sahlgrenska University Hospital, Gothenburg CF center, Gothenburg
NOT_YET_RECRUITING
University Hospitals Birmingham NHS Foundation Trust, Birmingham
NOT_YET_RECRUITING
Royal Brompton Hospital, London
NOT_YET_RECRUITING
University Hospital Southampton, Southampton
RECRUITING
UMC Utrecht, Utrecht
European Union
OTHER
Kors van der Ent
OTHER